Pascal Biosciences Inc. (TSXV:PAS) announced a non-brokered private placement of 406,250 units at a price of CAD 0.32 per unit for gross proceeds of CAD 130,000 on January 4, 2018. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the company at a price of CAD 0.40 per share for a period of twenty four months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the company may exercise once the units are free of resale restrictions and if the company’s shares are trading at or above a volume weighted average price of CAD 0.50 for 10 consecutive trading days, the warrants will expire upon 30 days from the date the company provides notice in writing to the warrant holders via a news release. Certain directors and officers of the company will participate in the transaction. The securities to be issued in the transaction will be subject to a four month hold period and the transaction is subject to the acceptance of the TSX Venture Exchange.